Burleson Research Technologies, Inc.
Dr. Burleson received his PhD from the Medical College of Wisconsin with Postdoctoral training at the University of Notre Dame. His background includes clinical experience at Milwaukee County General Hospital, academic appointments at the University of Notre Dame and North Carolina State University, government regulatory experience at the USEPA, and pharmaceutical experience in drug discovery at Procter & Gamble. He is President and CEO of BRT-Burleson Research Technologies, Inc. He is Co-Editor of Methods in Immunotoxicology, a member of the editorial board of the Journal of Immunotoxicology, Scientific Consultant, Science Review Board, US EPA. He served as President of the SOT Immunotoxicology Specialty Section and is past president of the Immunotoxicology Discussion Group. He has served as Chairman, Membership Committee, Immunotoxicology Specialty Section, SOT; Conference Chair, Immunotoxicology V Meeting; and Organizer, Immunotoxicology Continuing Education Course for the 19th Annual Society of Toxicologic Pathology Meeting. He serves several times a year for NIH-NIAID Grant and Contract Reviews.
Dr. Burleson received her PhD from the University of Notre Dame. She has over 20 years professional experience in immunotoxicology studies. Her background includes research at the National Institute of Environmental Health Sciences (NIEHS) and dermal molecular immunology studies at Procter and Gamble. She is presently Executive Vice President and Director of Laboratory Operations at BRT and has served as Study Director for GLP-compliant studies for pharmaceutical clients including host resistance studies and anti-fungal, bacterial, and viral evaluations, immunoassay development (ELISA) for immunogenicity studies, cytokine production, irritancy and hypersensitivity assays, LLNA, and interferon bioassays. She is a member of the Society of Toxicology (SOT), the American College of Toxicology (ACT), and of the International Journal of Toxicology editorial board.